Results 211 to 220 of about 2,221,794 (256)
Some of the next articles are maybe not open access.
Immunotherapy for Acute Myeloid Leukemia
Seminars in Hematology, 2015Despite longstanding efforts in basic research and clinical studies, the prognosis for patients with acute myeloid leukemia (AML) remains poor. About half of the patients are not medically fit for intensive induction therapy to induce a complete remission and are treated with palliative treatment concepts.
Lichtenegger, F.S. +3 more
openaire +3 more sources
Immunotherapy of Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology, 2001Most patients with acute myeloid leukemia (AML) respond initially to combination chemotherapy but later relapse. These patients often die from progressive disease or toxicities of further chemotherapy. At relapse, the patients' blasts are usually resistant to the drugs to which the patient has been exposed and frequently to other cytotoxic agents as ...
A E, Frankel +3 more
openaire +2 more sources
Acute myeloid leukemia in adults
Current Treatment Options in Oncology, 2000The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. Additional agents or substitution of high-dose cytarabine for conventional-dose cytarabine during induction does not improve the remission rate or overall survival. There is substantial toxicity with high-dose cytarabine during induction.
L D, Cripe, S, Hinton
openaire +2 more sources
Transplantation in Acute Myeloid Leukemia
Hematology/Oncology Clinics of North America, 2014Acute myeloid leukemia (AML) is associated with poor outcome mainly because of relapse. The best antileukemic treatment is allogeneic stem cell transplantation. However, the associated significant nonrelapse mortality limits both the application and outcome of the procedure.
Tsila, Zuckerman, Jacob M, Rowe
openaire +2 more sources
SEPHguarding acute myeloid leukemia
Cell Stem Cell, 2022Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this issue of Cell Stem Cell, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as an opportunity for targeted mitigation of malignant cell growth in AML.
Malini, Gupta, Britta, Will
openaire +2 more sources
Angiogenesis in acute myeloid leukemia
Blood, 2000We have read with interest the report of Padro et al[1][1] showing an increased angiogenesis in acute myeloid leukemia. Recently, other studies published in Blood also have shown that angiogenesis in acute myeloid leukemias is higher than in controls[2][2] and that it has an independent ...
DI RAIMONDO, FRANCESCO +3 more
openaire +3 more sources
Pharmacogenomics in Acute Myeloid Leukemia
Pharmacogenomics, 2009Acute myeloid leukemia (AML) in adults is a heterogeneous malignant pathology with a globally unfavorable prognosis. The classification of AML allows identification of subgroups with favorable prognosis. However, besides these specific subgroups, most patients will have an intermediate or unfavorable prognosis often resulting in induction failure ...
Christophe, Roumier, Meyling H, Cheok
openaire +2 more sources
Mayo Clinic Proceedings, 2006
Acute myeloid leukemia (AML) is a group of several different diseases, the treatment and outcome of which depend on several factors, including leukemia karyotype, patient age, and comorbid conditions. Despite advances in understanding the molecular biology of AML, its treatment remains challenging.
Elias J, Jabbour +2 more
openaire +2 more sources
Acute myeloid leukemia (AML) is a group of several different diseases, the treatment and outcome of which depend on several factors, including leukemia karyotype, patient age, and comorbid conditions. Despite advances in understanding the molecular biology of AML, its treatment remains challenging.
Elias J, Jabbour +2 more
openaire +2 more sources
Decitabine in Acute Myeloid Leukemia
Seminars in Hematology, 2005Standard induction chemotherapy, depending on patient tolerability, is at present the treatment of choice in patients with acute myeloid leukaemia (AML) under the age of 75 years. Since AML is a disease primarily of the elderly, a large proportion of patients do not receive this therapy; therefore, novel treatment modalities are warranted. In addition,
Lübbert, Michael, Minden, Mark
openaire +3 more sources
Immunophenotyping of Acute Myeloid Leukemia
2019Immunophenotyping by multiparameter flow cytometry is a rapid and efficient technique to simultaneously assess and correlate multiple individual cell properties like size and internal complexity along with antigen expression in a population of cells. This method is utilized for rapid characterization of the blasts and classification of acute myeloid ...
Pallavi Kanwar, Galera +2 more
openaire +2 more sources

